The Fox Tales

Main Menu

  • Home
  • Novel update
  • Novel books
  • Novel story
  • Novel list

The Fox Tales

Header Banner

The Fox Tales

  • Home
  • Novel update
  • Novel books
  • Novel story
  • Novel list
Novel update
Home›Novel update›Benitec Biopharma Inc. (NASDAQ:BNTC) Brief Update on Interests

Benitec Biopharma Inc. (NASDAQ:BNTC) Brief Update on Interests

By Jack N. Hernandez
April 15, 2022
0
0

Benitec Biopharma Inc. (NASDAQ: BNTC – Get a rating) benefited from a sharp rise in short-term interest rates in March. As of March 31, there was selling interest totaling 5,600 shares, an increase of 75.0% from the March 15 total of 3,200 shares. Approximately 0.1% of the company’s shares are sold short. Based on an average trading volume of 25,800 shares, the day-to-cover ratio is currently 0.2 days.

An institutional investor recently raised its position in Benitec Biopharma stock. Geode Capital Management LLC increased its stake in the shares of Benitec Biopharma Inc. (NASDAQ: BNTC – Get a rating) by 55.7% in Q3, according to the company in its latest 13F filing with the Securities and Exchange Commission. The fund held 53,692 shares of the biotech company after buying an additional 19,199 shares during the quarter. Geode Capital Management LLC owned 0.66% of Benitec Biopharma worth $191,000 when it last filed with the SEC. Institutional investors hold 20.15% of the company’s shares.

NASDAQ BNTC open at $2.00 on Fridays. The stock has a market capitalization of $16.33 million, a PE ratio of -0.01 and a beta of 1.44. Benitec Biopharma has a fifty-two week minimum of $1.90 and a fifty-two week maximum of $5.86. The company has a 50-day moving average price of $2.31 and a two-hundred-day moving average price of $2.82. The company has a quick ratio of 5.11, a current ratio of 5.11 and a leverage ratio of 0.06.

Separately, HC Wainwright began covering Benitec Biopharma in a Thursday, February 17 report. They issued a “buy” rating and a price target of $10.00 for the company.

Benitec Biopharma Company Profile (Get a rating)

Benitec Biopharma Inc, a development-stage biotechnology company, focuses on the development of new genetic drugs. The company develops DNA-directed RNA interference-based therapies for chronic and life-threatening human diseases. It is developing BB-301, an adeno-associated virus-based gene therapy agent for the treatment of oculo-pharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection.

See also



Get news and reviews for Benitec Biopharma Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Benitec Biopharma and related companies with MarketBeat.com’s FREE daily newsletter.

Related posts:

  1. Psychedelic Medicine Co. PharmaTher Provides 2022 Pipeline and Milestones Update
  2. Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Brief Update on Interests
  3. Legend Biotech Co. (NASDAQ:LEGN) Brief Update on Interests
  4. John Carpenter gives an update on the tales of a Halloween Night series

Categories

  • Novel books
  • Novel list
  • Novel story
  • Novel update

Recent Posts

  • Reacher Season 2 Story Details, Source Material Revealed
  • New Life Updated Wednesday, May 18, 2022
  • Preston House now on endangered historic places list | Community
  • Reed City author uses his mother’s letters to tell his story | News
  • 10 Best Horror Movies Based On Books

Archives

  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • January 2022
  • December 2021
  • November 2021
  • October 2021
  • September 2021
  • May 2021
  • April 2021
  • February 2021
  • December 2020
  • October 2020
  • September 2020
  • August 2020
  • June 2020
  • March 2020
  • February 2020
  • September 2019
  • June 2019
  • March 2019
  • February 2019
  • January 2019
  • December 2018
  • November 2018
  • October 2018
  • May 2018
  • November 2016
  • September 2016
  • May 2016
  • December 2015
  • September 2015
  • December 2014
  • July 2014
  • May 2014
  • March 2014
  • July 2013
  • Privacy Policy
  • Terms and Conditions